{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:04:59Z","timestamp":1791975899915,"version":"4.4.0"},"reference-count":79,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,12,25]],"date-time":"2020-12-25T00:00:00Z","timestamp":1608854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To summarize cases submitted to the 2019 Society for Hematopathology\/European Association for Haematopathology Workshop under the category of myeloid\/lymphoid neoplasms with eosinophilia and PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2 rearrangements, focusing on recent updates and relevant practice findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The cases were summarized according to their respective gene rearrangement to illustrate the spectrum of clinical, laboratory, and histopathology manifestations and to explore the appropriate molecular genetic tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Disease presentations were heterogeneous, including myeloproliferative neoplasms (MPNs), myelodysplastic syndromes (MDSs), MDS\/MPN, acute myeloid leukemia, acute B- or T-lymphoblastic lymphoma\/acute lymphoblastic lymphoma (ALL\/LBL), or mixed-lineage neoplasms. Frequent extramedullary involvement occurred. Eosinophilia was common but not invariably present. With the advancement of RNA sequencing, cryptic rearrangements were recognized in genes other than PDGFRA. Additional somatic mutations were more frequent in the FGFR1-rearranged cases. Cases with B-ALL presentations differed from Philadelphia-like B-ALL by the presence of an underlying MPN. Cases with FLT3 and ABL1 rearrangements could be potential candidates for future inclusion in this category.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Accurate diagnosis and classification of this category of myeloid\/lymphoid neoplasms has important therapeutic implications. With the large number of submitted cases, we expand our understanding of these rare neoplasms and improve our ability to diagnose these genetically defined disorders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajcp\/aqaa208","type":"journal-article","created":{"date-parts":[[2020,10,4]],"date-time":"2020-10-04T15:06:55Z","timestamp":1601824015000},"page":"160-178","source":"Crossref","is-referenced-by-count":72,"title":["Myeloid\/Lymphoid Neoplasms Associated With Eosinophilia and Rearrangements of\n                    <i>PDGFRA<\/i>\n                    ,\n                    <i>PDGFRB<\/i>\n                    , or\n                    <i>FGFR1<\/i>\n                    or With\n                    <i>PCM1-JAK2<\/i>"],"prefix":"10.1093","volume":"155","author":[{"given":"Olga","family":"Pozdnyakova","sequence":"first","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attilio","family":"Orazi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Texas Tech University Health Sciences Center, P. L. Foster School of Medicine, El Paso"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Kelemen","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"King","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaaren K","family":"Reichard","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona E","family":"Craig","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Quintanilla-Martinez","sequence":"additional","affiliation":[{"name":"Institute of Pathology and Neuropathology, Eberhard Karls University of T\u00fcbingen and Comprehensive Cancer Center, T\u00fcbingen University Hospital, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Rimsza","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy I","family":"George","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Utah School of Medicine, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Horny","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa A","family":"Wang","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,25]]},"reference":[{"key":"2021020409563117600_CIT0001","first-page":"72","article-title":"Myeloid\/lymphoid neoplasms with eosinophilia and rearrangements of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2.","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.","author":"Bain","year":"2017","edition":"Rev. 4th ed"},{"key":"2021020409563117600_CIT0002","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood."},{"key":"2021020409563117600_CIT0003","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2141.2011.09001.x","article-title":"Myeloid neoplasm with rearrangement of PDGFRA, but with no significant eosinophilia: should we broaden the World Health Organization definition of the entity?","volume":"156","author":"Rudzki","year":"2012","journal-title":"Br J Haematol."},{"key":"2021020409563117600_CIT0004","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.leukres.2005.11.011","article-title":"FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature","volume":"30","author":"Pardanani","year":"2006","journal-title":"Leuk Res."},{"key":"2021020409563117600_CIT0005","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1309\/AJCPMORR5Z2IKCEM","article-title":"Hematolymphoid neoplasms associated with rearrangements of PDGFRA, PDGFRB, and FGFR1","volume":"144","author":"Vega","year":"2015","journal-title":"Am J Clin Pathol."},{"key":"2021020409563117600_CIT0006","doi-asserted-by":"crossref","first-page":"e8001","DOI":"10.1097\/MD.0000000000008001","article-title":"Angioimmunoblastic T-cell lymphoma and hypereosinophilic syndrome with FIP1L1\/PDGFRA fusion gene effectively treated with imatinib: a case report","volume":"96","author":"Yamamoto","year":"2017","journal-title":"Medicine (Baltimore)."},{"key":"2021020409563117600_CIT0007","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/sj.leu.2404662","article-title":"Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma","volume":"21","author":"Metzgeroth","year":"2007","journal-title":"Leukemia."},{"key":"2021020409563117600_CIT0008","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00277-016-2598-x","article-title":"Diagnostic challenges in the work up of hypereosinophilia: pitfalls in bone marrow core biopsy interpretation","volume":"95","author":"Schwaab","year":"2016","journal-title":"Ann Hematol."},{"key":"2021020409563117600_CIT0009","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/PAS.0b013e31826df00b","article-title":"A case of nonleukemic myeloid sarcoma with FIP1L1-PDGFRA rearrangement: an unusual presentation of a rare disease","volume":"37","author":"Chen","year":"2013","journal-title":"Am J Surg Pathol."},{"key":"2021020409563117600_CIT0010","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.3324\/haematol.2017.165340","article-title":"Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome","volume":"102","author":"Wang","year":"2017","journal-title":"Haematologica."},{"key":"2021020409563117600_CIT0011","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1182\/blood-2004-03-0787","article-title":"FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia","volume":"104","author":"Pardanani","year":"2004","journal-title":"Blood."},{"key":"2021020409563117600_CIT0012","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.leukres.2005.11.014","article-title":"Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1\/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib","volume":"30","author":"Florian","year":"2006","journal-title":"Leuk Res."},{"key":"2021020409563117600_CIT0013","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cancergen.2017.10.004","article-title":"Myeloid neoplasm with eosinophilia associated with isolated extramedullary FIP1L1\/PDGFRA rearrangement","volume":"220","author":"Hilal","year":"2018","journal-title":"Cancer Genet."},{"key":"2021020409563117600_CIT0014","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med."},{"key":"2021020409563117600_CIT0015","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1182\/blood-2016-10-695973","article-title":"Myeloid neoplasms with eosinophilia","volume":"129","author":"Reiter","year":"2017","journal-title":"Blood."},{"key":"2021020409563117600_CIT0016","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.hoc.2017.04.009","article-title":"Tyrosine kinase inhibitors in the treatment of eosinophilic neoplasms and systemic mastocytosis","volume":"31","author":"Gotlib","year":"2017","journal-title":"Hematol Oncol Clin North Am."},{"key":"2021020409563117600_CIT0017","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1600-0609.2012.01799.x","article-title":"Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement","volume":"89","author":"Arefi","year":"2012","journal-title":"Eur J Haematol."},{"key":"2021020409563117600_CIT0018","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3324\/haematol.11187","article-title":"TV6 and PDGFRB: a license to fuse","volume":"92","author":"Lierman","year":"2007","journal-title":"Haematologica."},{"key":"2021020409563117600_CIT0019","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.3324\/haematol.2014.105452","article-title":"PDGFRB-rearranged T-lymphoblastic leukemia\/lymphoma occurring with myeloid neoplasms: the missing link supporting a stem cell origin","volume":"99","author":"Ondrejka","year":"2014","journal-title":"Haematologica."},{"key":"2021020409563117600_CIT0020","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/bjh.12834","article-title":"ATF7IP as a novel PDGFRB fusion partner in acute lymphoblastic leukaemia in children","volume":"165","author":"Kobayashi","year":"2014","journal-title":"Br J Haematol."},{"key":"2021020409563117600_CIT0021","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N Engl J Med."},{"key":"2021020409563117600_CIT0022","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/ajh.25617","article-title":"World Health Organization\u2013defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management","volume":"94","author":"Shomali","year":"2019","journal-title":"Am J Hematol."},{"key":"2021020409563117600_CIT0023","doi-asserted-by":"crossref","DOI":"10.1111\/his.14097","article-title":"Systematic use of fluorescence in situ hybridization (FISH) and clinicopathological features in the screening of PDGFRB rearrangements of patients with myeloid\/lymphoid neoplasms","author":"Fang","year":"2020;76:1042-1054","journal-title":"Histopathology"},{"key":"2021020409563117600_CIT0024","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000046641","article-title":"Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor beta","volume":"107","author":"Steer","year":"2002","journal-title":"Acta Haematol."},{"key":"2021020409563117600_CIT0025","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1038\/leu.2017.240","article-title":"Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia","volume":"31","author":"Jawhar","year":"2017","journal-title":"Leukemia."},{"key":"2021020409563117600_CIT0026","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1365-2141.2008.07294.x","article-title":"Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study","volume":"143","author":"Metzgeroth","year":"2008","journal-title":"Br J Haematol."},{"key":"2021020409563117600_CIT0027","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s12032-011-9831-1","article-title":"Imatinib mesylate may induce long-term clinical response in FIP1L1-PDGFR\u03b1-negative hypereosinophilic syndrome","volume":"29","author":"Helbig","year":"2012","journal-title":"Med Oncol."},{"key":"2021020409563117600_CIT0028","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/00000478-199203000-00003","article-title":"T-cell lymphoblastic lymphoma with eosinophilia associated with subsequent myeloid malignancy","volume":"16","author":"Abruzzo","year":"1992","journal-title":"Am J Surg Pathol."},{"key":"2021020409563117600_CIT0029","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.humpath.2009.11.003","article-title":"8p11 myeloproliferative syndrome: a review","volume":"41","author":"Jackson","year":"2010","journal-title":"Hum Pathol."},{"key":"2021020409563117600_CIT0030","doi-asserted-by":"crossref","DOI":"10.1080\/10428194.2017.1397663","article-title":"Myeloid\/lymphoid neoplasms with FGFR1 rearrangement","author":"Strati","year":"2018;59:1672-1676","journal-title":"Leuk Lymphoma."},{"key":"2021020409563117600_CIT0031","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/PAS.0b013e31814b226e","article-title":"t(8;13)-positive bilineal lymphomas: report of 6 cases","volume":"32","author":"Vega","year":"2008","journal-title":"Am J Surg Pathol."},{"key":"2021020409563117600_CIT0032","first-page":"1628","article-title":"A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: a review","volume":"9","author":"Macdonald","year":"1995","journal-title":"Leukemia."},{"key":"2021020409563117600_CIT0033","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1182\/blood.V85.7.1881.bloodjournal8571881","article-title":"A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia\/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity","volume":"85","author":"Inhorn","year":"1995","journal-title":"Blood."},{"key":"2021020409563117600_CIT0034","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.humpath.2017.10.019","article-title":"FGFR1 translocation with concurrent myeloproliferative neoplasm, systemic mastocytosis, and lymphoblastic lymphoma: a case report","volume":"74","author":"Chang","year":"2018","journal-title":"Hum Pathol."},{"key":"2021020409563117600_CIT0035","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.leukres.2011.10.009","article-title":"Unique association of systemic mastocytosis and myeloid\/lymphoid neoplasm in blast crisis with abnormality of FGFR1 gene","volume":"36","author":"Mayeur-Rousse","year":"2012","journal-title":"Leuk Res."},{"key":"2021020409563117600_CIT0036","first-page":"801","article-title":"Systemic mastocytosis with associated myeloproliferative neoplasm with t(8;19)(p12;q13.1) and abnormality of FGFR1: report of a unique case","volume":"7","author":"Duckworth","year":"2014","journal-title":"Int J Clin Exp Pathol."},{"key":"2021020409563117600_CIT0037","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ajh.23296","article-title":"Myeloid and lymphoid neoplasms with FGFR1 abnormalities: diagnostic and therapeutic challenges","volume":"88","author":"Savage","year":"2013","journal-title":"Am J Hematol."},{"key":"2021020409563117600_CIT0038","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.humpath.2017.05.008","article-title":"Myeloproliferative neoplasms with t(8;22)(p11.2;q11.2)\/BCR-FGFR1: a meta-analysis of 20 cases shows cytogenetic progression with B-lymphoid blast phase","volume":"65","author":"Montenegro-Garreaud","year":"2017","journal-title":"Hum Pathol."},{"key":"2021020409563117600_CIT0039","doi-asserted-by":"crossref","first-page":"708","DOI":"10.6004\/jnccn.2016.0072","article-title":"Cytogenetic evolution associated with disease progression in hematopoietic neoplasms with t(8;22)(p11;q11)\/BCR-FGFR1 rearrangement","volume":"14","author":"Wang","year":"2016","journal-title":"J Natl Compr Canc Netw."},{"key":"2021020409563117600_CIT0040","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000363441","article-title":"8p11 myeloproliferative syndrome with t(1;8)(q25;p11.2): a case report and review of the literature","volume":"133","author":"Kim","year":"2015","journal-title":"Acta Haematol."},{"key":"2021020409563117600_CIT0041","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/leu.2012.286","article-title":"A translocation t(2;8)(q12;p11) fuses FGFR1 to a novel partner gene, RANBP2\/NUP358, in a myeloproliferative\/myelodysplastic neoplasm","volume":"27","author":"Gervais","year":"2013","journal-title":"Leukemia."},{"key":"2021020409563117600_CIT0042","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/leu.2009.79","article-title":"LRRFIP1, a new FGFR1 partner gene associated with 8p11 myeloproliferative syndrome","volume":"23","author":"Soler","year":"2009","journal-title":"Leukemia."},{"key":"2021020409563117600_CIT0043","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1182\/blood.V93.4.1381","article-title":"The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1","volume":"93","author":"Popovici","year":"1999","journal-title":"Blood."},{"key":"2021020409563117600_CIT0044","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/gcc.20144","article-title":"8p11 myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of the FGFR1 and TIF1 genes","volume":"42","author":"Belloni","year":"2005","journal-title":"Genes Chromosomes Cancer."},{"key":"2021020409563117600_CIT0045","doi-asserted-by":"crossref","first-page":"922","DOI":"10.3324\/haematol.2010.036558","article-title":"The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia\/lymphoma and t(7;8)(q22;p11)","volume":"96","author":"Wasag","year":"2011","journal-title":"Haematologica."},{"key":"2021020409563117600_CIT0046","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1182\/blood.V95.5.1788.005k15_1788_1796","article-title":"FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33)","volume":"95","author":"Guasch","year":"2000","journal-title":"Blood."},{"key":"2021020409563117600_CIT0047","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/gcc.1177","article-title":"Identification of four new translocations involving FGFR1 in myeloid disorders","volume":"32","author":"Sohal","year":"2001","journal-title":"Genes Chromosomes Cancer."},{"key":"2021020409563117600_CIT0048","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/sj.leu.2403712","article-title":"The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1","volume":"19","author":"Walz","year":"2005","journal-title":"Leukemia."},{"key":"2021020409563117600_CIT0049","first-page":"265","article-title":"Philadelphia chromosome-negative chronic myelogenous leukemia in a child with t(8;9)(p11 or 12;q34)","volume":"5","author":"Lewis","year":"1983","journal-title":"Am J Pediatr Hematol Oncol."},{"key":"2021020409563117600_CIT0050","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/gcc.20023","article-title":"Identification of a novel gene, FGFR1OP2, fused to FGFR1 in 8p11 myeloproliferative syndrome","volume":"40","author":"Grand","year":"2004","journal-title":"Genes Chromosomes Cancer."},{"key":"2021020409563117600_CIT0051","first-page":"802","article-title":"Blastic T\/Myeloid neoplasm associated with ZMYM2-FGFR1","volume-title":"Diagnostic Pathology: Lymph Nodes and Extranodal Lymphomas.","author":"Miranda","year":"2017","edition":"2nd ed"},{"key":"2021020409563117600_CIT0052","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1073\/pnas.95.10.5712","article-title":"Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13)","volume":"95","author":"Popovici","year":"1998","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2021020409563117600_CIT0053","first-page":"e348","article-title":"Molecular genetic characterization of myeloid\/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2","volume-title":"Haematologica.","author":"Baer","year":"2018"},{"key":"2021020409563117600_CIT0054","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.3892\/mmr.2017.6140","article-title":"Activity of fibroblast growth factor receptor inhibitors TKI258, ponatinib and AZD4547 against TPRFGFR1 fusion","volume":"15","author":"Qiu","year":"2017","journal-title":"Mol Med Rep."},{"key":"2021020409563117600_CIT0055","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1093\/annonc\/mdy173","article-title":"Treatment of the myeloid\/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor","volume":"29","author":"Verstovsek","year":"2018","journal-title":"Ann Oncol."},{"key":"2021020409563117600_CIT0056","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1158\/0008-5472.CAN-04-4263","article-title":"The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2","volume":"65","author":"Reiter","year":"2005","journal-title":"Cancer Res."},{"key":"2021020409563117600_CIT0057","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/bjh.12963","article-title":"Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities?","volume":"166","author":"Bain","year":"2014","journal-title":"Br J Haematol."},{"key":"2021020409563117600_CIT0058","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41379-018-0165-9","article-title":"Hematopoietic neoplasms with 9p24\/JAK2 rearrangement: a multicenter study","volume":"32","author":"Tang","year":"2019","journal-title":"Mod Pathol."},{"key":"2021020409563117600_CIT0059","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ajh.2830340113","article-title":"Neutrophilic myelofibrosis presenting as Philadelphia chromosome negative BCR non-rearranged chronic myeloid leukemia","volume":"34","author":"Stewart","year":"1990","journal-title":"Am J Hematol."},{"key":"2021020409563117600_CIT0060","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00277-014-2221-y","article-title":"Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes","volume":"94","author":"Schwaab","year":"2015","journal-title":"Ann Hematol."},{"key":"2021020409563117600_CIT0061","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1200\/JCO.2012.46.4370","article-title":"Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene","volume":"31","author":"Rumi","year":"2013","journal-title":"J Clin Oncol."},{"key":"2021020409563117600_CIT0062","doi-asserted-by":"crossref","first-page":"151405","DOI":"10.1016\/j.anndiagpath.2019.151405","article-title":"Myeloid neoplasm with eosinophilia and BCR-JAK2\/t(9;22)(p24;q11.2) morphologically mimicking chronic myeloid leukemia","volume":"44","author":"Thakral","year":"2020","journal-title":"Ann Diagn Pathol."},{"key":"2021020409563117600_CIT0063","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.cancergen.2016.03.002","article-title":"BCR-JAK2 fusion in a myeloproliferative neoplasm with associated eosinophilia","volume":"209","author":"He","year":"2016","journal-title":"Cancer Genet."},{"key":"2021020409563117600_CIT0064","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s12185-015-1792-2","article-title":"Myelodysplastic syndrome with t(9;22)(p24;q11.2), a BCR-JAK2 fusion: case report and review of the literature","volume":"102","author":"Kantarcioglu","year":"2015","journal-title":"Int J Hematol."},{"key":"2021020409563117600_CIT0065","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/10428194.2019.1658105","article-title":"Myeloid neoplasm with eosinophilia and ETV6-JAK2 fusion","volume":"61","author":"Cook","year":"2020","journal-title":"Leuk Lymphoma."},{"key":"2021020409563117600_CIT0066","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.exphem.2007.08.025","article-title":"Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V&gt;F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms","volume":"35","author":"Najfeld","year":"2007","journal-title":"Exp Hematol."},{"key":"2021020409563117600_CIT0067","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s00277-012-1431-4","article-title":"Detection of ETV6 gene rearrangements in adult acute lymphoblastic leukemia","volume":"91","author":"Zhou","year":"2012","journal-title":"Ann Hematol."},{"key":"2021020409563117600_CIT0068","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1182\/blood-2018-04-841676","article-title":"Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children\u2019s Oncology Group","volume":"132","author":"Roberts","year":"2018","journal-title":"Blood."},{"key":"2021020409563117600_CIT0069","first-page":"1657","article-title":"Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL","volume":"1","author":"Roberts","year":"2017","journal-title":"Blood Adv."},{"key":"2021020409563117600_CIT0070","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00277-015-2451-7","article-title":"Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene","volume":"94","author":"Rumi","year":"2015","journal-title":"Ann Hematol."},{"key":"2021020409563117600_CIT0071","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/sj.leu.2404266","article-title":"FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation","volume":"20","author":"Vu","year":"2006","journal-title":"Leukemia."},{"key":"2021020409563117600_CIT0072","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cancergen.2017.05.001","article-title":"A novel TRIP11-FLT3 fusion in a patient with a myeloid\/lymphoid neoplasm with eosinophilia","volume":"216-217","author":"Chung","year":"2017","journal-title":"Cancer Genet"},{"key":"2021020409563117600_CIT0073","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/leu.2016.304","article-title":"A novel t(3;13)(q13;q12) translocation fusing FLT3 with GOLGB1: toward myeloid\/lymphoid neoplasms with eosinophilia and rearrangement of FLT3?","volume":"31","author":"Troadec","year":"2017","journal-title":"Leukemia."},{"key":"2021020409563117600_CIT0074","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.exphem.2007.07.002","article-title":"A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy","volume":"35","author":"Grand","year":"2007","journal-title":"Exp Hematol."},{"key":"2021020409563117600_CIT0075","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1182\/blood-2011-03-343426","article-title":"Response of ETV6-FLT3-positive myeloid\/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3","volume":"118","author":"Walz","year":"2011","journal-title":"Blood."},{"key":"2021020409563117600_CIT0076","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/1098-2264(2000)9999:9999<1::AID-GCC1089>3.0.CO;2-1","article-title":"Molecular cytogenetic and clinical findings in ETV6\/ABL1-positive leukemia","volume":"30","author":"Van Limbergen","year":"2001","journal-title":"Genes Chromosomes Cancer."},{"key":"2021020409563117600_CIT0077","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40364-016-0070-7","article-title":"A novel three-way rearrangement involving ETV6 (12p13) and ABL1 (9q34) with an unknown partner on 3p25 resulting in a possible ETV6-ABL1 fusion in a patient with acute myeloid leukemia: a case report and a review of the literature","volume":"4","author":"Tirado","year":"2016","journal-title":"Biomark Res."},{"key":"2021020409563117600_CIT0078","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cancergen.2018.08.002","article-title":"Myeloproliferative neoplasm with ABL1\/ETV6 rearrangement mimics chronic myeloid leukemia and responds to tyrosine kinase inhibitors","volume":"228-229","author":"Xie","year":"2018","journal-title":"Cancer Genet."},{"key":"2021020409563117600_CIT0079","doi-asserted-by":"crossref","first-page":"e412","DOI":"10.1038\/bcj.2016.11","article-title":"Myeloproliferative neoplasm with eosinophilia and T-lymphoblastic lymphoma with ETV6-LYN gene fusion","volume":"6","author":"Telford","year":"2016","journal-title":"Blood Cancer J."}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajcp\/article-pdf\/155\/2\/160\/36186746\/aqaa208.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajcp\/article-pdf\/155\/2\/160\/36186746\/aqaa208.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T06:25:20Z","timestamp":1612765520000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/155\/2\/160\/6046533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,25]]},"references-count":79,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,12,25]]},"published-print":{"date-parts":[[2021,2,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqaa208","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,2,1]]},"published":{"date-parts":[[2020,12,25]]}}}